Evaluation and treatment of patients with parasitic infections
Official title: Evaluation, Treatment, and Monitoring of Patients With Known or Suspected Parasitic Infection
Run by National Institutes of Health Clinical Center (CC) · NCT00001645 · Data updated 2026-11-12
This study is testing how to better treat and monitor people with parasitic infections like malaria and intestinal worms, focusing on personalized care for anyone aged 1 and older.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 3 Years and up |
| Sex | All |
| Enrollment | 800 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Status | Recruiting |
| Started | October 10, 1998 |
| Registry record updated | November 3, 2026 |
| Trial ID | NCT00001645 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals aged 1 year and older with clinical evidence suggestive of a parasitic infection.
✕Probably not a fit
Patients under 3 years of age or those without evidence of a parasitic infection may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate, treat, and monitor patients who have known or suspected parasitic infections, such as malaria and intestinal worms. Participants, aged 1 year and older, will undergo physical examinations and various laboratory tests, including blood, stool, and urine analyses. The study will follow a prospective design, allowing for individualized treatment plans based on each patient's specific condition, while adhering to standard medical practices. Patients may also be referred to other studies if more appropriate for their needs.
Why it matters
Potential benefit: If successful, this study could improve the diagnosis and management of parasitic infections, leading to better patient outcomes.
How similar studies have gone: Other studies have shown success in evaluating and treating parasitic infections, indicating that this approach is supported by existing research.
Who can join: the full rules
Show full inclusion / exclusion criteria
* INCLUSION CRITERIA: Age 3 or over. Access to a primary medical care provider outside of the NIH Clinical evidence suggestive of a parasitic infection EXCLUSION CRITERIA: Less than 3 years of age No evidence suggestive of a parasitic infection
Where it's running
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting
Study contacts
- Principal investigator: Thomas B Nutman, M.D. — National Institute of Allergy and Infectious Diseases (NIAID)
- Study coordinator: Thomas B Nutman, M.D.
- Email: tnutman@mail.nih.gov
- Phone: (301) 496-5399
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Lotilaner safety and blood activity in healthy adults in Mali
This Phase 1b study tests if a single dose of lotilaner is safe, tolerable, and shows mosquito-killing activity in healthy adults living in Mali.
-
See if the R21/Matrix-M malaria vaccine works in real-world settings for kids under 5
This study tests how well the R21/Matrix-M vaccine protects children under 5 in Burkina Faso and Uganda when used in typical clinical care.
-
Do malaria vaccines lower the risk of invasive non-typhoidal Salmonella in young children?
This study will see if the R21/Matrix-M malaria vaccine lowers the chance of invasive non-typhoidal Salmonella disease in children under 5 who come to health facilities with fever in the Kisantu Health Zone (DRC).
-
Community spread of multiple infectious diseases in Cambodia from a One Health perspective
This project will test how common and connected dengue, chikungunya, Zika, Japanese encephalitis, and West Nile infections are among people, animals, and the environment across Cambodia.
-
Lower-dose and alternate-schedule RTS,S malaria vaccine for young children
This project will test if smaller doses and different schedules of the RTS,S malaria vaccine are safe and help build immunity in healthy children aged 5 to 60 months who live where malaria is common.
-
Optimizing malaria and HIV treatment for children in Busia and Kampala
We will test whether dolutegravir affects growth and how it interacts with common malaria medicines in children with and without HIV, following them for two years in Busia and Kampala.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.